Skip to main content
Jacques Galipeau, MD, Hematology, Madison, WI, University Hospital

JacquesGalipeauMD

Hematology Madison, WI

Associate Dean for Therapeutics Development, University of Wisconsin - Madison School of Medicine and Public Health. Hematologist, Department of Medicine

Dr. Galipeau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Galipeau's full profile

Already have an account?

Summary

  • Jacques Galipeau, M.D. FRCP(C) obtained his Medical Degree from the University of Montreal and completed specialty training in internal medicine at McGill University. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology & Medical Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children’s research hospital in Memphis Tennessee.

    Starting in 1997, Dr. Galipeau served as faculty at McGill University before joining Emory University in 2009 as a Professor of Hematology & Oncology and Director of the Emory Personalized Immunotherapy Center. Since September 2016, he has been the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is the inaugural Associate Dean for Therapeutics Discovery and Development at the University of Wisconsin School of Medicine & Public Health

    Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease.

    He is also the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.

    Dr. Galipeau is a board certified Hematologist with an active clinical practice in consultative benign hematology.

Clinical Expertise

  • Hematology, Regenerative medicine, General / Benign hematology, experimental cell therapy, virus specific T-cells, mesenchymal stromal cells, first-in-human clinical trials

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
  • University of Montreal Faculty of Medicine
    University of Montreal Faculty of MedicineClass of 1988

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2016 - 2025
  • GA State Medical License
    GA State Medical License 2009 - 2017
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • GRA Distinguished Cancer Scientist 2009
  • Fonds de la recherche en sante du Quebec chercheur-boursier senior 2006
  • Excellence in Research Sir Mortimer B. Davis Jewish General Hospital, 2004
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • GM-CSF and IL-4 fusion cytokine Induces B Cell-dependent Hematopoietic Regeneration  
    Jiusheng Deng, Andrea Pennati, Shala Yuan, Jian Hui Wu, Krishnendu Roy, Edmund Waller, Jacques Galipeau, Mol Ther, 1/1/2017
  • Bone Marrow Derived Mesenchymal Stromal Cells From Sickle Cell Disease Patients Display Intact Functionality  
    Elizabeth O. Stenger, Raghavan Chinnadurai, Shala Yuan, Marco Garcia, Dalia Arafat, Greg Gibson, Lakshmanan Krishnamurti, and Jacques Galipeau, Biol Blood Marrow Transplant, 1/1/2017
  • GIFT4 Fusokine Converts Leukemic B Cells into Anti-CLL Effectors  
    Jiusheng Deng, Andrea Pennati, Yuanqiang Wu, Jonathon B. Cohen, Spencer Ng, Jian Hui Wu, Christopher R. Flowers, and Jacques Galipeau, J Transl Med, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • The MSC conundrum of unmet translational expectations-analysis and potential fixes. 
    Boston, MA - 1/29/2016
  • MSCs: Ability, Potency and Comparability. 
    St. Jude Children’s Research Hospital, Memphis, TN - 1/29/2016
  • MSC product for clinical trials: manufacturing and potency considerations. 
    Boston, MA - 1/27/2016
  • Join now to see all

Other

  • La therapie genique: D’un enthousiasme excessif a un optimisme prudent. Invited contribution to a series on genomics 
    Galipeau, J., Massie B., Langelier Y., Piche A., Tanguay R.M., Le Devoir (a French language Montreal newspaper)
    1/29/2000

Press Mentions

  • The Future of Cell Therapy: Novel Study Tests Treatment for Radiation-Induced Dry Mouth
    The Future of Cell Therapy: Novel Study Tests Treatment for Radiation-Induced Dry MouthMay 31st, 2022
  • UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry Mouth
    UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry MouthSeptember 8th, 2020
  • ONLINE: Taking down Cancer with Tech
    ONLINE: Taking down Cancer with TechAugust 18th, 2020
  • Join now to see all

Other Languages

  • French

Hospital Affiliations